Orchard Therapeutics plc (ORTX) Financial Analysis & Valuation | Quarter Chart
Orchard Therapeutics plc (ORTX)
ORTXPrice: $16.7
Fair Value: 🔒
🔒score
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gen... more
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-... more
Description
Shares
| Market Cap | $380.11M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Hubert Baburaj Gaspar |
| IPO Date | 2018-10-31 | CAGR | — |
| Employees | 166 | Website | www.orchard-tx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.24% | Total Yield | 0.24% |
ORTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $200.90M | P/E Ratio | -4.07 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 54.41 | P/B Ratio | 2.17 |
| P/CF Ratio | -2.81 | P/FCF Ratio | -4.61 |
| EPS | $-4.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 35.21% | Gross Margin | 0.65% |
| Operating Margin | -4.52% | Profit Margin | -1.13% |
| ROE | -0.05% | ROA | -0.04% |
| ROCE | -0.2% | Current Ratio | 2.78 |
| Quick Ratio | 2.72 | Cash Ratio | 1.13 |
| Debt/Equity | 0.59 | Interest Coverage | -33.86 |
| Altman Z Score | -3.08 | Piotroski Score | 5 |